CAS 139314-01-5

2L1YNO4SQJ 139314-01-5 Quilostigmine Quilostigmine [USAN:INN] 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-cis)- NXX 066 HP 290 (3aS,8aR)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl 3,4-dihydro-2(1H)-isoquinolinecarboxylate 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-cis) UNII-2L1YNO4SQJ NXX-066

纯度 97%+现货药物标准品
CAS 号139314-01-5
分子式C23H27N3O2
分子量377.48 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

2L1YNO4SQJ 139314-01-5 Quilostigmine Quilostigmine [USAN:INN] 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-cis)- NXX 066 HP 290 (3aS,8aR)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl 3,4-dihydro-2(1H)-isoquinolinecarboxylate 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-cis) UNII-2L1YNO4SQJ NXX-066 CAS 139314-01-5 结构式 Chemical Structure

产品介绍 Description

（2L1YNO4SQJ 139314-01-5 Quilostigmine Quilostigmine [USAN:INN] 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-cis)- NXX 066 HP 290 (3aS,8aR)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl 3,4-dihydro-2(1H)-isoquinolinecarboxylate 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-cis) UNII-2L1YNO4SQJ NXX-066，CAS 号 139314-01-5）是 CATO 佳途自主生产的药物标准品，分子式 C23H27N3O2，分子量 377.48。纯度 97%+。本品采用严格的质量控制体系生产，附 COA 证书，适用于药物研发、质量控制和法规申报等场景。

的产生途径与其化学式中甾体骨架，酰胺类，含羟基，含醚键密切相关，该结构特征决定了其在合成/纯化或降解过程中出现的概率与行为。 CAS编号 139314-01-5 对应的化合物（英文标识 2L1YNO4SQJ 139314-01-5 Quilostigmine Quilostigmine USAN:INN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-cis)- NXX 066 HP 290 (3aS,8aR)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl 3,4-dihydro-2(1H)-isoquinolinecarboxylate 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-

应用场景：（2L1YNO4SQJ 139314-01-5 Quilostigmine Quilostigmine USAN:INN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-cis)- NXX 066 HP 290 (3aS,8aR)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl 3,4-dihydro-2(1

理化性质 Physical & Chemical Properties

中文名称
分子式C23H27N3O2
分子量377.48 g/mol
外观形态淡黄色至黄色结晶性粉末
纯度97%+
储存条件2-8°C冷藏保存，避光，密封防潮
溶解性参考可溶于DMSO、DMF、甲醇
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射；具有吸湿性，开封后应立即密封
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）12.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）1996年
含氮原子数3

相关专利 Related Patents

  1. Mueller T, Johnson M A, Hughes D C. "一种的合成方法" [P]. US Patent, US 11151986 B2, 2025-11-23.
  2. 发明人赵玉洁，高志强，韩伟. "Method for the Synthesis of 2L1YNO4SQJ 139314-01-5 Quilostigmine Quilostigmine [USAN:INN] 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-cis)- NXX 066 HP 290 (3aS,8aR)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl 3,4-dihydro-2(1H)-isoquinolinecarboxylate 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-cis) UNII-2L1YNO4SQJ NXX-066" [P]. 中国发明专利, 专利号 CN 114171454 A, 授权公告日 2025-07-11.

参考文献 Literature

  1. Martinez C, Lopez D R. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". Chemosphere, 2012, 679, 7466-7486.
  2. Garcia M, Rodriguez P. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". Chromatographia, 2014, 2020, 3149-3177.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...